|
Q2 FY2024
As of Nov 30, 2023
|
Q1 FY2024
As of Aug 31, 2023
|
Q4 FY2023
As of May 31, 2023
|
Q3 FY2023
As of Feb 28, 2023
|
Q2 FY2023
As of Nov 30, 2022
|
Q1 FY2023
As of Aug 31, 2022
|
Q4 FY2022
As of May 31, 2022
|
Q3 FY2022
As of Feb 28, 2022
|
Q2 FY2022
As of Nov 30, 2021
|
Q1 FY2022
As of Aug 31, 2021
|
Q4 FY2021
As of May 31, 2021
|
Q4 FY2018
As of May 31, 2018
|
Q3 FY2018
As of Feb 28, 2018
|
Q2 FY2018
As of Nov 30, 2017
|
Q1 FY2018
As of Aug 31, 2017
|
Q4 FY2017
As of May 31, 2017
|
Q3 FY2017
As of Feb 28, 2017
|
Q2 FY2017
As of Nov 30, 2016
|
Q1 FY2017
As of Aug 31, 2016
|
Q4 FY2016
As of May 31, 2016
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Digital currency | ||||||||||||||||||||
| Equipment, net | ||||||||||||||||||||
| License, net | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable and accrued liabilities - related party | ||||||||||||||||||||
| Note payable, net of $0 debt discount as of May 31,2017 and 2016, respectively | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Accrued interest - related party | ||||||||||||||||||||
| Accrued management fees - related party | ||||||||||||||||||||
| Loans payable | ||||||||||||||||||||
| Convertible notes, net of discount -current | ||||||||||||||||||||
| Loan payable -related party | ||||||||||||||||||||
| Notes payable - related party | ||||||||||||||||||||
| Convertible notes, net of discount | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Total Current liabilities | ||||||||||||||||||||
| Convertible notes, net of $0 and $100,205 debt discount as of May 31, 2016 and 2015, respectively | ||||||||||||||||||||
| Promissory notes, net of discount -noncurrent | ||||||||||||||||||||
| Note payable - related party-noncurrent | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Commitments | ||||||||||||||||||||
| Stockholders' Deficit | ||||||||||||||||||||
| Preferred stock, value | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Series D Preferred Stock | ||||||||||||||||||||
| Series E Preferred Stock | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Common Stock, Par Value $0.001, 6,500,000,000 shares authorized, and 3,313,024,616 and 3,208,024,616 issued and outstanding, respectively | ||||||||||||||||||||
| Common stock payables | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
Loading...
